Polo-like Kinase 1 Inhibition as a Therapeutic Approach to Selectively Target BRCA1-Deficient Cancer Cells by Synthetic Lethality Induction

Sofía Carbajosa, María Florencia Pansa, Natalia Paviolo, Andrés M. Castellaro, Diego L. Andino, Ayelén D. Nigra, Iris Alejandra García, Ana C. Racca, Lucía Rodriguez-Berdini, Virginia Angiolini, Laura Guantay, Florencia Villafañez (+11 others)
2019 Clinical Cancer Research  
BRCA1 and BRCA2 deficiencies are widespread drivers of human cancers that await the development of targeted therapies. We aimed to identify novel synthetic lethal relationships with therapeutic potential using BRCA-deficient isogenic backgrounds.
doi:10.1158/1078-0432.ccr-18-3516 pmid:30890549 fatcat:4jdjyvbre5ejnpnx6ibsi6k7qm